The once-daily oral GLP-1 RA orforglipron produces clinically and statistically significant weight loss and cardiometabolic ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss. Objective: Obesity affects more than 40 ...

New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. While Ozempic can be ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced risk for obesity-related ...

Weight loss drug treatment has relatively low adherence. Despite experts advocating for lifelong adherence, more than half of ...

Recently, tennis legend Serena Williams opened up about using weight-loss medication, aiming to break the ‘stigma’ around such treatments. The 43-year-old, who has won 23 Grand Slam titles and is the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists have protective effects in ...

PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction ...

Overweight and obesity are chronic metabolic diseases characterized by excessive fat accumulation in the body. The pathogenesis of overweight and obesity includes genetic, metabolic, environmental, ...